A Korean HealthTech company can enter Southeast Asia with strong clinical results, a working diagnostic, and a willing customer, then discover that the real failure begins after the product succeeds. That is because positive result may actually trigger a chain the local healthcare system cannot reliably complete: confirmation, specialist referral, treatment, and payment. This then creates an uncomfortable market-entry question for founders and investors: what is a successful test worth if the patient has nowhere practical to go next?
Korean HealthTech Is Reaching Further Into Southeast Asia
Korean healthcare companies have more reason to look abroad as medical-device exports recover. According to the Korea Health Industry Development Institute’s first-half 2026 export analysis, South Korean medical-device exports reached USD 3.08 billion during the first six months of 2026, up 5.9% compared with the same period a year earlier.
Thailand is among the markets receiving increased attention. The 2026 Korea-Thailand Biohealth Partnership organized by KOTRA and Korean industry partners brought Korean pharmaceutical and medical-device companies into meetings with Thai buyers and healthcare organizations in September, including businesses working in digital healthcare and AI diagnostics.
Now, those meetings may be able to establish commercial interest, but they cannot answer a more difficult question on their own: what happens around a healthcare product once it enters the local system?
Tanrada “Ink” Pansuwan, Investment Manager at Disrupt Health Impact Fund, evaluates global HealthTech opportunities with a perspective shaped by both neuroscience research and venture investment. In an exclusive interview with ngopihangat, she identified the surrounding care pathway as one of the factors that can change the meaning of an otherwise strong technology during Southeast Asian expansion.
“A recurring pattern is that the technology is genuinely strong, but the surrounding care pathway does not transfer directly.”
A Product Can Travel Without Its Original Care Pathway
Pansuwan said an investor assessing cross-border potential first needs to determine if the underlying clinical need exists in the destination market. The product must also function across relevant patient populations, local infrastructure and realistic care settings, while the assumptions supporting its original use may need to be reconsidered.
A technology designed inside one healthcare system can depend on processes that are easy to overlook because they sit outside the product itself. Those processes can include the route into diagnosis, specialist availability, patient behavior, reimbursement arrangements and the sequence of care triggered after a result is produced.
This becomes particularly important for diagnostic and screening technologies. A device can identify a potential problem accurately, yet the health benefit still depends on the system being able to act on that information.
The World Health Organization’s July 2026 cancer guidance describes cancer screening as a process for identifying findings suggestive of cancer or precancer in people without symptoms. Abnormal findings require additional diagnostic evaluation, while confirmed cancer requires referral into treatment.
The test therefore represents one stage of a longer clinical sequence. Expanding the availability of detection does not automatically expand the capacity required after detection.
Cancer Screening Exposes the Risk After a Positive Result
Pansuwan highlighted early cancer detection as an example of a technology whose clinical value cannot be judged only by its ability to identify risk.
“The science may be compelling and potentially clinically valuable, but we still need to ask what happens after a positive result.”
A positive result can create demand for confirmatory testing, specialist consultation and treatment. If those services are difficult to access, the technology may expose a clinical problem sooner without necessarily creating an equally accessible route for resolving it.
Thailand provides a useful example because the country has already built substantial cancer-screening infrastructure. The WHO report on cervical cancer elimination in Thailand says HPV-based screening has been used nationally since 2020, self-collection was introduced in 2023, and the Cancer Anywhere initiative has sought to improve access to cancer services.
Yet the same report identifies continuing gaps linked to rural access, socioeconomic conditions, late-stage diagnosis, referral networks and oncology capacity. Screening access has expanded, but the ability to move patients through diagnosis and subsequent care remains uneven.
Thailand recorded cervical-screening coverage of 83.4% among the target population during the 2020–2024 phase. Government inspection data cited by WHO also showed that 63.7% of women with abnormal screening results in 2024 received colposcopy, while reporting on subsequent treatment remained incomplete.
Together, the figures point to different stages of the care pathway. Reaching more people with screening does not by itself show how consistently an abnormal result can move through confirmation and into appropriate care.
At-Home Testing Can Remove One Barrier and Reveal Another
The same problem can appear when HealthTech moves testing away from hospitals and clinics. Pansuwan noted that at-home testing may enter markets where patients have traditionally depended more heavily on face-to-face healthcare, changing the support required around the product.
Thailand has already begun incorporating self-sampling into cervical-cancer prevention. The Thai Department of Medical Sciences reported HPV DNA self-sampling activities in 2026, extending specimen collection beyond conventional clinical encounters.
A 2026 study of HPV self-sampling in Kulon Progo, Indonesia shows what can happen after that access barrier is reduced. The study involved 2,056 women across 21 primary-care units and reported 99.1% acceptance of self-sampling.
But then the next stage was less seamless. Among participants who required further assessment, some declined colposcopy while others had technically invalid examinations. High acceptance at the testing stage therefore did not guarantee completion of the diagnostic pathway.
For a startup entering a new healthcare market, the relevant map extends beyond product usage. It includes how patients receive results, where they are directed next, which clinical resources are available, and how reliably the system can move an abnormal finding toward confirmation and care.
Pansuwan summarized the commercial challenge:
“What needs to be reconsidered first is the end-to-end care pathway: who uses the product, what evidence is required, who pays, and what happens next.”
A Care-Pathway Gap May Change the Market Entry Strategy Before the Product
A weak care pathway does not always force a startup to redesign its technology. In Pansuwan’s experience, the first adjustment is often commercial.
“We have not yet seen a company completely change its product because the surrounding care pathway was not sufficiently established.
More commonly, companies adapt the use case or go-to-market strategy, for example, applying the same technology to a different disease indication, or starting with direct-to-consumer adoption to build evidence before pursuing enterprise customers or reimbursement.”
Cancer screening offers one possible route. A company may begin where patients already have easier access to the diagnostic services required after an abnormal result rather than immediately pursuing the broadest possible market.
“In cancer screening, this may mean initially targeting self-pay or premium health-check markets where downstream diagnostic work-up is more accessible.”
The implication for HealthTech market entry is more precise than simply choosing a country with a large patient population. A commercially viable starting point may instead be the segment where the surrounding care pathway can already carry the product’s result into the next clinical step.
One Southeast Asian Market Can Hand the Same Test a Different Job
A diagnostic may arrive in Southeast Asia with the same technology, clinical purpose and disease target, yet enter a very different chain of care in each market.
Thailand’s HPV screening and self-sampling programs, for example, sit inside an established national screening framework. But elsewhere, access to screening, specialists and referral services may be structured differently or remain less developed.
That changes more than distribution. It can alter who introduces the test to patients, where samples are collected, who communicates an abnormal result, how confirmatory care is reached and which institution ultimately carries responsibility for the next step.
A Southeast Asia expansion strategy therefore cannot stop at proving that the product itself travels. HealthTech companies need to map the clinical sequence their product depends on and identify which parts of that sequence must already exist locally, which can be rebuilt with partners, and which assumptions from the home market no longer hold.
Korean HealthTech Founders Need to Separate Product Advantage From System Advantage
This is especially relevant for Korean HealthTech startups that already have domestic clinical results, regulatory progress and commercial traction. Those achievements can establish credibility, but they may also reflect conditions that are specific to Korea’s healthcare system.
Pansuwan said her assessment of internationally expanding companies includes examining which advantages remain intact outside their home environment.
“Finally, we distinguish advantages inherent to the technology from those dependent on Korea-specific pricing, partnerships, regulation, or healthcare-system dynamics.”
A proprietary diagnostic mechanism, manufacturing capability or technical function may travel relatively well. But the same cannot automatically be assumed for the referral route surrounding it, the institution purchasing it, patient expectations, access to confirmation, or the commercial relationships that helped the product succeed in Korea.
Korean founders preparing for Southeast Asian expansion must therefore ask a more demanding question than simply “Does our technology work here?” They need to determine how much of the Korean success case belongs to the technology itself and how much belongs to the healthcare system that has been carrying it.
The Result Is Not the Finish Line
HealthTech commercialization often treats successful detection as evidence that a difficult technical problem has been solved. Cross-border expansion exposes another layer of risk because the product can arrive much faster than the clinical system surrounding its result.
That is why the stronger opportunity may belong to companies that design market entry around the next decision a patient or clinician has to make once the technology works. After all, in healthcare, a result only becomes valuable when the system can do something actually useful with it.
Key Takeaway
- Korean HealthTech Southeast Asia expansion requires care-pathway testing, not only product testing. A technology can retain its technical performance while entering a healthcare system that handles diagnosis, referral and treatment differently.
- Cancer screening demonstrates the post-result challenge clearly. WHO guidance treats abnormal screening as the beginning of additional diagnostic and treatment steps, not the endpoint of care.
- Thailand shows that screening access and downstream capacity are separate issues. The country has national HPV screening, self-sampling and Cancer Anywhere initiatives while continuing to address referral, workforce and geographic access gaps.
- At-home testing can remove a front-end barrier without automatically solving follow-up. Indonesian HPV self-sampling research reported 99.1% acceptance while still encountering challenges during subsequent assessment.
- Ink Pansuwan’s investor lens focuses on the entire care pathway. Companies may need to change the initial use case, customer segment or market-entry route when the surrounding healthcare system does not support the original pathway.
- Korean founders should separate technology advantages from Korea-specific system advantages. Pricing, partnerships, regulation and healthcare structures that support domestic traction may not accompany the product into another market.
– Stay Ahead in Korea’s Startup Scene –
Get real-time insights, funding updates, and policy shifts shaping Korea’s innovation ecosystem.
➡️ Follow ngopihangat on LinkedIn, X (Twitter), Threads, Bluesky, Telegram, Facebook, and WhatsApp Channel.
🤝 Looking to connect with verified Korean companies building globally?
Explore curated company profiles and request direct introductions through beSUCCESS Connect.
PakarPBN
A Private Blog Network (PBN) is a collection of websites that are controlled by a single individual or organization and used primarily to build backlinks to a “money site” in order to influence its ranking in search engines such as Google. The core idea behind a PBN is based on the importance of backlinks in Google’s ranking algorithm. Since Google views backlinks as signals of authority and trust, some website owners attempt to artificially create these signals through a controlled network of sites.
In a typical PBN setup, the owner acquires expired or aged domains that already have existing authority, backlinks, and history. These domains are rebuilt with new content and hosted separately, often using different IP addresses, hosting providers, themes, and ownership details to make them appear unrelated. Within the content published on these sites, links are strategically placed that point to the main website the owner wants to rank higher. By doing this, the owner attempts to pass link equity (also known as “link juice”) from the PBN sites to the target website.
The purpose of a PBN is to give the impression that the target website is naturally earning links from multiple independent sources. If done effectively, this can temporarily improve keyword rankings, increase organic visibility, and drive more traffic from search results.
